cubeb

Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, cubeb perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream cubeb before arriving at the liver. It is during this first pass in its native form that it is believed cubeb to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day 0 to Day 30.3

Genentech and Novartis are developing an anti-IgE monoclonal antibody for asthma and allergic rhinitis. In December 1999 they announced positive study results. This is evidence that reducing IgE results in cubeb a reduction of symptoms associated with IgE-mediated allergic disease.13 For people who find they cannot adequately avoid the allergens, the symptoms often can be controlled with medications. Effective medications cubeb that can be prescribed by a physician include antihistamines, topical nasal steroids, and cromolyn sodium - any of which can be used alone or in combination. Many effective antihistamines and cubeb and cubeb decongestants also are available without a prescription. Click here for allergy medication online.

In 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average cubeb IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 cubeb to 395 (the same period, one year after the first set of symptom diaries). The active group cubeb had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7